Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GlaxoSmithKline PakistanKAR:GLAXO -0.58%93 Debt-to-EBITDA is 0.02 as of Mar. 2026, which is 100% above its 10-year median of 0.01. GuruFocus rates KAR:GLAXO with a GF Score™ of 93/100 and a GF Value™ of ₨323.45 (Fairly Valued). The stock has 1 warning sign investors should review. Among 690 Drug Manufacturers companies, GlaxoSmithKline Pakistan ranks better than 97.39% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for GlaxoSmithKline Pakistan's Debt-to-EBITDA or its related term are showing as below:
KAR:GLAXO'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01 Med: 0.01 Max: 0.05
Current: 0.02
During the past 13 years, the highest Debt-to-EBITDA Ratio of GlaxoSmithKline Pakistan was 0.05. The lowest was 0.01. And the median was 0.01.
KAR:GLAXO's Debt-to-EBITDA is ranked better than 97.39% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.65
vs KAR:GLAXO: 0.02
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
GlaxoSmithKline Pakistan Debt-to-EBITDA Related Terms
GlaxoSmithKline Pakistan Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:GLAXO vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Debt-to-EBITDA of 0.02 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on GlaxoSmithKline Pakistan. This is 100% above median its historical median of 0.01. Over the past decade, GlaxoSmithKline Pakistan's Debt-to-EBITDA has ranged from 0.01 to 0.05. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #18 out of 690 companies in the Drug Manufacturers industry, placing it in the top 2.6%.
Is GlaxoSmithKline Pakistan's Debt-to-EBITDA too high?
GlaxoSmithKline Pakistan's current Debt-to-EBITDA of 0.02 is 100% above median its 10-year median of 0.01. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.05. The Drug Manufacturers industry median Debt-to-EBITDA is 1.65. GlaxoSmithKline Pakistan's value of 0.02 is 98.8% below this industry median. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #18 out of 690 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #18 out of 690 companies for Debt-to-EBITDA. This places GlaxoSmithKline Pakistan in the top 3% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.65. GlaxoSmithKline Pakistan's value of 0.02 is 98.8% below this benchmark. Historically, GlaxoSmithKline Pakistan's own Debt-to-EBITDA has ranged from 0.01 to 0.05 over the past decade. While the company's 10-year median is 0.01 vs. the industry median of 1.65, GlaxoSmithKline Pakistan has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current Debt-to-EBITDA of 0.02 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on GlaxoSmithKline Pakistan. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current Debt-to-EBITDA is 0.02, which is 100% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₨323.45, compared to a current price of ₨342.65 — trading 5.9% above its estimated fair value. The current Debt-to-EBITDA is 0.02, which is 100% above median its 10-year median of 0.01 and 98.8% below the Drug Manufacturers industry median of 1.65. GlaxoSmithKline Pakistan's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Debt-to-EBITDA is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨342.65 is trading 5.9% above its estimated GF Value™ of ₨323.45.
GuruFocus considers GlaxoSmithKline Pakistan to be Fairly Valued.
Key valuation signals for KAR:GLAXO:
Debt-to-EBITDA: 0.02 (100% above median its 10-year median of 0.01)
GF Value™: ₨323.45 vs. price of ₨342.65 (5.9% above fair value)
Industry Position: 98.8% below the Drug Manufacturers median (#18 of 690)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
93GF Score
Get the complete analysis for KAR:GLAXO
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
